0.05Open0.05Pre Close0 Volume1 Open Interest5.00Strike Price0.00Turnover195.40%IV95.74%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1071Delta0.1591Gamma51.60Leverage Ratio-0.0055Theta0.0001Rho5.53Eff Leverage0.0011Vega
Corvus Pharmaceuticals Stock Discussion
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
NEWS
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
No comment yet